JOP. J Pancreas (Online) 2008; 9(2):197-202.
Rechallenge with Cisplatin in a Patient with Pancreatic Cancer Who Developed a Hypersensitivity Reaction to Oxaliplatin. Is Skin Test Useful in this Setting?
Kyle T Elligers, Marianne Davies, Desiree Sanchis, Thomas Ferencz, Muhammad Wasif Saif
Yale University School of Medicine. New Haven, CT, USA
Context A recent meta-analysis suggests that the addition of oxaliplatin or cisplatin to gemcitabine can lead to improved survival in patients with advanced pancreatic cancer, especially those with a good performance status. In an event of a platinum hypersensitivity reaction, the particular platinum salt is likely discontinued. Desensitization has shown benefit anecdotically but it is an intensive process. We present a case in which platinum-containing therapy was able to continue in a patient with metastatic pancreatic cancer following a hypersensitivity reaction to oxaliplatin, by switching to cisplatin after a negative intradermal skin test.
Case report A 58-year-old gentleman with metastatic pancreatic adenocarcinoma received biweekly cycles of gemcitabine in combination with oxaliplatin. During the fifth cycle, he experienced a grade 2 hypersensitivity reaction including erythema and lip numbness, for which he was medicated with antihistaminics and corticosteroids. Cycles 6 and 7 of oxaliplatin were tolerated over 4 h infusion with pretreatment of H1, H2 blockers and corticosteroids. During the 8th cycle, the patient developed a grade 3 hypersensitivity reaction manifesting as facial flushing, sweating, symptomatic bronchospasm, cyanotic lips and chest tightness. Symptoms resolved with antihistaminics, corticosteroids and epinephrine. Although oxaliplatin treatment was discontinued, the patient’s response to the platinum therapy merited a cisplatin rechallenge. An intradermal skin test was administered with negative result, allowing for a regimen change to biweekly gemcitabine and cisplatin. The patient has tolerated multiple additional cycles with further decrease in tumor size and tumor markers.
Conclusions Intradermal skin tests can be useful tools for effectual rechallenge. Literature review reveals scarce data of intradermal skin tests used to rechallenge cisplatin to patients with oxaliplatin hypersensitivity reaction, and our case is the first apparent example for a patient with advanced pancreatic cancer. Despite the possibility of platinum cross-reactivity, rechallenge can be considered if patients have responded to the therapy and are treated in a supervised environment.
|Full text:||HTML format PDF format|
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13. [More details]
Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007; 18:1652-9. [More details]
Saif MW, Kim R. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opin Pharmacother 2007; 8:2719-27. [More details]
Saif MW. Hypersensitivity reactions associated with oxaliplatin. Expert Opin Drug Saf 2006; 5:687-94. [More details]
National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0. (CTCAE). Publish date August 9, 2006. [More details]
Markman M, Zanotti K, Peterson G, Kulp B, Webster K, Belinson J. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003; 21:4611-4. [More details]
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509-16. [More details]
Wrzesinski SH, McGurk ML, Donovan CT, Ferencz TM, Saif MW. Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate. Anticancer Drugs 2007l; 18:721-4. [More details]
Goldberg A, Confino-Cohen R, Fishman A, Beyth Y, Altaras M. A modified, prolonged desensitization protocol in carboplatin allergy. J Allergy Clin Immunol 1996; 98:841-3. [More details]
Meyer L, Zuberbier T, Worm M, Oettle H, Riess H. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002; 20:1146-7. [More details]
Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24:3946-52. [More details]
Saif MW. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007. JOP. J Pancreas (Online) 2007; 8:365-73. [More details]
Xie DR, Liang HL, Wang Y, Guo SS, Yang Q. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol 2006; 12:6973-81. [More details]
Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24:253-62. [More details]
Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003; 89:477-81. [More details]
Siu SW, Chan RT, Au GK. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 2006; 17:259-61. [More details]
Gowda A, Goel R, Berdzik J, Leichman CG, Javle M. Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 2004; 18:1671-5. [More details]
Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003; 97:2301-7. [More details]
Koren C, Yerushalmi R, Katz A, Malik H, Sulkes A, Fenig E. Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol 2002; 25:625-6. [More details]
Shlebak AA, Clark PI, Green JA. Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol 1995; 35:349-51. [More details]
Markman M. Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf 2003; 2:597-607. [More details]
Stahl M, Köster W, Wilke H. Reaction after oxaliplatin--prevention with corticosteroids? Ann Oncol 2001; 12:874. [More details]
Zanotti KM, Markman M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf 2001; 24:767-79. [More details]
Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007; 25:4028-9. [More details]
Porzio G, Marchetti P, Paris I, Narducci F, Ricevuto E, Ficorella C. Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin. Eur J Gynaecol Oncol 2002; 23:335-6. [More details]
Gottlieb MJ, Nelson B, Perry W. Utility of skin test for allergy to carboplatin or cisplatin. J Allergy Clin Immunol 1998; 101:S139. [More details]
Leguy-Seguin V, Jolimoy G, Coudert B, Pernot C, Dalac S, Vabres P, Collet E. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol 2007; 119:726-30. [More details]
Keywords Anaphylaxis; Bronchial Spasm; Cisplatin; Exanthema; Hypersensitivity; oxaliplatin; Pancreatic Neoplasms; Skin Tests
Correspondence Muhammad Wasif Saif: firstname.lastname@example.org